Literature DB >> 31054500

Assessing cognitive performance in radiologically isolated syndrome.

Shay Menascu1, Maya Stern2, Roi Aloni2, Alon Kalron2, David Magalshvili3, Anat Achiron4.   

Abstract

BACKGROUND: Radiologically isolated syndrome (RIS) is defined as the occurrence of incidental brain MRI lesions suggestive of multiple sclerosis (MS) in otherwise healthy subjects without any signs or symptoms that could indicate to the disease. We evaluated cognitive performance in a cohort of RIS patients.
METHODS: A retrospective analysis of prospectively collected data from a population-based registry documenting demographic, clinical and imaging data of MS patients followed at our institution. Cognitive performance of subjects diagnosed with RIS according to Okuda's criteria was evaluated. Cognitive assessment was performed using MindStreams Global Assessment Battery to evaluate memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills, and compared to that of age- and education-matched healthy population.
RESULTS: Thirty patients diagnosed with RIS, mean age at first MRI, 34.3 ± 1.9 years, and disease follow up ranging from 1 to 15 years, were included in the study. Eight patients (26.6%) converted to MS within 4.2 ± 1.4 years. Cognitive performance was relatively preserved with a mean global cognitive score of 98.4 ± 1.6 (median, 100), but all cognitive measurements were below the mean performance for age- and education-matched healthy population. Similar to MS patients, information processing speed was the most impaired cognitive function, mean 94.7 ± 2.04, median 94. Cognitive performance did not differ between RIS patients who converted to MS and those who remained with sustained RIS.
CONCLUSIONS: Cognitive performance in RIS subjects was below average for age- and education-matched norms. Information processing speed was the most impaired cognitive test. Cognitive performance of RIS subjects should be followed closely in order to identify any changes that may indicate conversion to MS.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cognitive function; Information processing speed; Multiple sclerosis; Radiologically isolated syndrome

Mesh:

Year:  2019        PMID: 31054500     DOI: 10.1016/j.msard.2019.04.030

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  6 in total

1.  Using advanced analysis of multifocal visual-evoked potentials to evaluate the risk of clinical progression in patients with radiologically isolated syndrome.

Authors:  J M Miguel; M Roldán; C Pérez-Rico; M Ortiz; L Boquete; R Blanco
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

Review 2.  Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis.

Authors:  Maria Pia Amato; Nicola De Stefano; Matilde Inglese; Emanuele Morena; Giovanni Ristori; Marco Salvetti; Maria Trojano
Journal:  Front Neurol       Date:  2022-03-14       Impact factor: 4.003

3.  Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.

Authors:  Arwa Rekik; Mona Aissi; Islem Rekik; Mariem Mhiri; Mahbouba Ayed Frih
Journal:  Brain Behav       Date:  2022-04-10       Impact factor: 3.405

4.  The relationship between cognition, education, and employment in multiple sclerosis patients.

Authors:  Devon S Conway; Robert A Bermel; Sarah M Planchon
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-08-05

Review 5.  The multiple sclerosis prodrome.

Authors:  Naila Makhani; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2021-06-21       Impact factor: 42.937

6.  Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.

Authors:  Jiwon Oh; Suradech Suthiphosuwan; Pascal Sati; Martina Absinta; Blake Dewey; Melanie Guenette; Daniel Selchen; Aditya Bharatha; Emily Donaldson; Daniel S Reich; Anthony Feinstein
Journal:  Mult Scler       Date:  2021-03-23       Impact factor: 6.312

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.